These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 22054386)

  • 21. Low Cost, Low Dose, Oral, Neoadjuvant Chemotherapy Protocol in Locally Advanced Borderline Oral Cancers-Feasibility Study.
    Sultania M; Deo SVS; Shukla NK; Sharma A; Sahoo R; Bhasker S
    Indian J Surg Oncol; 2021 Mar; 12(1):67-72. PubMed ID: 33814834
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activity and safety of KEES - an oral multi-drug chemo-hormonal metronomic combination regimen in metastatic castration-resistant prostate cancer.
    Asowed M; Elander NO; Pettersson L; Ekholm M; Papantoniou D
    BMC Cancer; 2023 Apr; 23(1):309. PubMed ID: 37016322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metronomic Chemotherapy for Advanced Prostate Cancer: A Literature Review.
    Parshad S; Sidhu AK; Khan N; Naoum A; Emmenegger U
    J Clin Med; 2022 May; 11(10):. PubMed ID: 35628909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification and Characterization of Key Differentially Expressed Genes Associated With Metronomic Dosing of Topotecan in Human Prostate Cancer.
    Mitra Ghosh T; White J; Davis J; Mazumder S; Kansom T; Skarupa E; Barnett GS; Piazza GA; Bird RC; Mitra AK; Yates C; Cummings BS; Arnold RD
    Front Pharmacol; 2021; 12():736951. PubMed ID: 34938177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience.
    Simsek C; Esin E; Yalcin S
    J Oncol; 2019; 2019():5483791. PubMed ID: 31015835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes of Oral Metronomic Therapy in Patients with Lymphomas.
    Mailankody S; Ganesan P; Joshi A; Ganesan TS; Radhakrishnan V; Dhanushkodi M; Mehra N; Kalaiyarasi JP; Kannan K; Sagar TG
    Indian J Hematol Blood Transfus; 2019 Jan; 35(1):50-56. PubMed ID: 30828148
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metronomic oral cyclosphosphamide as third-line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma.
    Lee VHF; Kwong DLW; Lam KO; Lai YC; Li Y; Tong CC; Ho PPY; Chan WL; Wong LS; Leung DKC; Chan SY; Chan FT; Leung TW; Lee AWM
    Medicine (Baltimore); 2017 Apr; 96(15):e6518. PubMed ID: 28403082
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients.
    Di Desidero T; Derosa L; Galli L; Orlandi P; Fontana A; Fioravanti A; Marconcini R; Giorgi M; Campi B; Saba A; Lucchesi S; Felipetto R; Danesi R; Francia G; Allegrini G; Falcone A; Bocci G
    Invest New Drugs; 2016 Dec; 34(6):760-770. PubMed ID: 27557783
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metronomic cyclophosphamide therapy in hormone-naive patients with non-metastatic biochemical recurrent prostate cancer: a phase II trial.
    Calcagno F; Mouillet G; Adotevi O; Maurina T; Nguyen T; Montcuquet P; Curtit E; Kleinclauss F; Pivot X; Borg C; Thiery-Vuillemin A
    Med Oncol; 2016 Aug; 33(8):89. PubMed ID: 27400698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quality of life in patients with metastatic breast cancer treated with metronomic chemotherapy.
    Perroud HA; Alasino CM; Rico MJ; Queralt F; Pezzotto SM; Rozados VR; Scharovsky OG
    Future Oncol; 2016 May; 12(10):1233-42. PubMed ID: 26948919
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.
    Barroso-Sousa R; da Fonseca LG; Souza KT; Chaves AC; Kann AG; de Castro G; Dzik C
    Med Oncol; 2015 Jan; 32(1):443. PubMed ID: 25519824
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metronomics: towards personalized chemotherapy?
    André N; Carré M; Pasquier E
    Nat Rev Clin Oncol; 2014 Jul; 11(7):413-31. PubMed ID: 24913374
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study.
    Briasoulis E; Aravantinos G; Kouvatseas G; Pappas P; Biziota E; Sainis I; Makatsoris T; Varthalitis I; Xanthakis I; Vassias A; Klouvas G; Boukovinas I; Fountzilas G; Syrigos KN; Kalofonos H; Samantas E
    BMC Cancer; 2013 May; 13():263. PubMed ID: 23718900
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.
    Zhang HL; Ye DW; Yao XD; Dai B; Zhang SL; Shen YJ; Zhu Y; Zhang W
    Urol Int; 2007; 79(4):307-11. PubMed ID: 18025847
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.
    Derosa L; Galli L; Orlandi P; Fioravanti A; Di Desidero T; Fontana A; Antonuzzo A; Biasco E; Farnesi A; Marconcini R; Francia G; Danesi R; Falcone A; Bocci G
    Cancer; 2014 Dec; 120(24):3923-31. PubMed ID: 25111199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure.
    Ladoire S; Eymard JC; Zanetta S; Mignot G; Martin E; Kermarrec I; Mourey E; Michel F; Cormier L; Ghiringhelli F
    Anticancer Res; 2010 Oct; 30(10):4317-23. PubMed ID: 21036758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral/metronomic cyclophosphamide-based chemotherapy as option for patients with castration-refractory prostate cancer: review of the literature.
    Nelius T; Rinard K; Filleur S
    Cancer Treat Rev; 2011 Oct; 37(6):444-55. PubMed ID: 21277093
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current second-line treatment options for patients with castration resistant prostate cancer (CRPC) resistant to docetaxel.
    Arsov C; Winter C; Rabenalt R; Albers P
    Urol Oncol; 2012; 30(6):762-71. PubMed ID: 20884252
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Salvage therapy with oral metronomic cyclophosphamide and methotrexate for castration-refractory metastatic adenocarcinoma of the prostate resistant to docetaxel.
    Gebbia V; Serretta V; Borsellino N; Valerio MR;
    Urology; 2011 Nov; 78(5):1125-30. PubMed ID: 22054386
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.